IP Library Granted Patent US 7,214,662
Granted Patent B2
US 7,214,662 · App. 10/279,625 · Granted May 8, 2007

Injectable solution of an LHRH antagonist

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,214,662
App. No.
10/279,625
Granted
May 8, 2007
Kind
B2
Abstract

An aqueous injectable soution of an LHRH antagonist, such as Cetrorelix, in an organic, pharmaceutically acceptable acid, such as gluconic acid.

Claims (10)

1. An aqueous solution of about 500 mg of one LHRH antagonist or a combination of LHRH antagonists selected from the group consisting of cetrorelix, teverelix, D-63153 (Ac-D-Nal-D-pCl-Phe-D-Pal-Ser-N-Me-Tyr-D-Hci-Nle-Arg-Pro-D-Ala-NH2), ganirelix, abarelix, antide, and azaline; about 2.4 g of an acid selected from the group consisting of carboxylic acid, hydroxycarboxylic acid, gluconic acid, and gluconic acid deltalactone; about 2.0 g Tween 80; about 95 g mannitol; in water; to form a solution with a volume of about 10 mL to 2 Liters.

2. An aqueous solution of about 500 mg D-63153; about 100 mg Tween 80; about 475 mg mannitol; in water; to form a solution with a volume of about 10 mL to 2 Liters.

3. An aqueous solution of about 100 mg teverelix; about 100 mg Tween 80; about 475 mg mannitol; in water; to form a solution with a volume of about 10 mL to 2 Liters.

4. The aqueous injectable solution of claim 1 , wherein the acid is gluconic acid deltalactone.

5. The aqueous injectable solution of claim 1 , wherein the LHRH antagonist is Cetrorelix and the acid is gluconic acid deltalactone.

6. The aqueous injectable solution of claim 1 , wherein the volume of the aqueous injectable solution is about 10 mL.

7. A method for producing an aqueous injectable solution of an LHRH antagonist or a combination of LHRH antagonists, as in any of claims 1 – 3 , 4 – 5 , or 6 , which comprises either (a) compounding an injectable solution of an LHRH antagonist; Tween; and mannitol in a pharmaceutically acceptable organic acid and water; or (b) dissolving an LHRH antagonist; Tween; and mannitol in a pharmaceutically acceptable organic acid; homogenizing the resulting solution; and recovering it in an injectable form.

8. The method of claim 7 , wherein said acid is a carboxylic acid.

9. The method of claim 8 , wherein said acid is hydroxycarboxylie acid.

10. The method of claim 9 , wherein said acid is gluconic acid deltalactone.

Assignments (9)
SECURITY AGREEMENT Recorded Nov 22, 2011
From: ZENTARIS IVF GMBH
To: CETRO INVESTORS, L.P.
Reel/Frame 027278/0053 →
SECURITY AGREEMENT Recorded Nov 22, 2011
From: COWEN HEALTHCARE ROYALTY PARTNERS, L.P. (SUCCESSOR OF CETRO INVESTORS, L.P.); VANDERBILT ROYALTY HOLDINGS L.P.; VANDERBILT ROYALTY SUB L.P.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 027278/0184 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2010
From: AETERNA ZENTARIS GMBH
To: ZENTARIS IVF GMBH
Reel/Frame 025017/0268 →
CHANGE OF NAME Recorded Jun 15, 2010
From: ZENTARIS GMBH
To: AETERNA ZENTARIS GMBH
Reel/Frame 024537/0876 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2007
From: SARLIKIOTIS, WERNER; BAUER, HORST; RISCHER, MATTHIAS; ENGEL, JURGEN; GUTHLEIN, FRANK; DI STEFANO, DOMINIQUE
To: ZENTARIS GMBH
Reel/Frame 019043/0098 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2005
From: SARLIKIOTIS, WERNER; BAUER, HORST; RISCHER, MATTHIAS; ENGLE, JURGEN; GUTHLEIN, FRANK; DI STEFANO, DMINIQUE
To: ZENTARIS GMBH
Reel/Frame 016305/0779 →
CHANGE OF NAME Recorded Jul 12, 2004
From: ZENTARIS AG
To: ZENTARIS GMBH
Reel/Frame 014836/0597 →
CHANGE OF NAME Recorded Jun 17, 2004
From: ZENTARIS AG
To: ZENTARIS GMBH
Reel/Frame 015460/0561 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2002
From: SARLIKIOTIS, WERNER; BAUR, HORST; RISCHER, MATTHIAS; ENGEL, JURGEN
To: ZENTARIS AG
Reel/Frame 013460/0440 →